Tetrasubstituted imidazole inhibitors of cytokine release: Probing substituents in the N-1 position

Journal of Medicinal Chemistry

Volumn 47, Issue 25, 2004, Pages 6311-6325

  Laufer, Stefan A ^a   Zimmermann, Werner ^a   Ruff, Kathrin J ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 5 (4 PYRIDINYL) 4 (4 FLUOROPHENYL) 1 (4 PIPERIDINYL)IMIDAZOLE; ACETAMIDE DERIVATIVE; ADALIMUMAB; CYTOCHROME P450; CYTOKINE; ETANERCEPT; IMIDAZOLE DERIVATIVE; IMIDAZOLE INHIBITOR; INFLIXIMAB; INTERLEUKIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE; N [4 [5 (4 FLUOROPHENYL) 3 (3 METHOXYETHYL) 2 METHYLSULFANYL 3H IMIDAZOL 4 YL]PYRIDIN 3 YL]ACETAMIDE; PROTEIN INHIBITOR; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SB 216995; SYNAPTOPHYSIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG CROSS REACTIVITY; DRUG POTENCY; ENZYME BINDING; ENZYME INDUCTION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; INHIBITION KINETICS; LIVER CELL;

AMINOPYRIDINES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BINDING SITES; CYTOCHROME P-450 ENZYME SYSTEM; CYTOKINES; HUMANS; IMIDAZOLES; INTERLEUKIN-1; ISOENZYMES; MODELS, MOLECULAR; MOLECULAR CONFORMATION; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PYRIDINES; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR NECROSIS FACTOR-ALPHA;

EID: 9744265656     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0496584     Document Type: Article

References (43)

1. Vervoordeldonk Margriet, J. B. M.; Tak, P. P. Cytokines in rheumatoid arthritis. Curr. Rheumatol. Rep. 2002, 4, 208-217.
2. Foster, M. L.; Halley, F.; Souness, J. E. Potential of p38 inhibitors in the treatment of rheumatoid arthritis. Drug News Perspectives 2000, 13, 488-497.
3. Pargellis, C.; Regan, J. Inhibitors of p38 mitogen-activated protein kinase for the treatment of rheumatoid arthritis. Curr. Opin. Invest. Drugs 2003, 4, 566-571.
4. Orchard, S. Kinases as targets: Prospects for chronic therapy. Curr. Opin. Drug Discovery Dev. 2002, 5, 713-717.
5. Lubberts, E.; Van den Berg, W. B. Cytokines in the pathogenesis of rheumatoid arthritis and collagen-induced arthritis. Adv. Exp. Med. Biol. 2003, 520, 194-202.
6. Moreland, L. W.; Schiff, M. H.; Baumgartner, S. W.; Tindall, E. A.; Fleischmann, R. M.; Bulpitt, K. J.; Weaver, A. L.; Keystone, E. C.; Furst, D. E.; Mease, P. J.; Ruderman, E. M.; Horwitz, D. A.; Arkfeld, D. G.; Garrison, L.; Burge, D. J.; Blosch, C. M.; Lange, M. L.; McDonnell, N. D.; Weinblatt, M. E. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann. Intern. Med. 1999, 130, 478-486.
7. Weinblatt, M. E.; Keystone, E. C.; Furst, D. E.; Moreland, L. W.; Weisman, M. H.; Birbara, C. A.; Teoh, L. A.; Fischkoff, S. A.; Chartash, E. K. Adalimumab, a fully human antitumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis Rheumatism 2003, 48, 35-45.
8. Maini, R.; St Clair, E. W.; Breedveld, F.; Furst, D.; Kalden, J.; Weisman, M.; Smolen, J.; Emery, P.; Harriman, G.; Feldmann, M.; Lipsky, P. Infliximab (chimeric antitumor necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial. ATTRACT Study Group. Lancet 1999, 354, 1932-1939.
9. Yazdani, C.; McLaughlin, T.; Cummins, G.; Doyle, J. Comparison of rheumatoid arthritis care costs in patients starting therapy with leflunomide versus etanercept. Am. J. Manag. Care 2001, 7, 419-426.
10. Lee, J. C.; Kumar, S.; Griswold, D. E.; Underwood, D. C.; Votta, B. J.; Adams, J. L. Inhibition of p38 MAP kinase as a therapeutic strategy. Immunopharmacology 2000, 47, 185-201.
11. Lee, J. C.; Laydon, J. T.; McDonnell, P. C.; Gallagher, T. F.; Kumar, S.; Green, D.; McNulty, D.; Blumenthal, M. J.; Heyes, J. R. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature (London) 1994, 372, 739-746.
12. Young, P.; McDonnell, P.; Dunnington, D.; Hand, A.; Laydon, J.; Lee, J. Pyridinyl imidazoles inhibit IL-1 and TNF production at the protein level. Agents Actions 1993, 39, 67-9.
13. Pearson, G.; Robinson, F.; Gibson, T. B.; Xu, B. E.; Karandikar, M.; Berman, K.; Cobb, M. H. Mitogen-activated protein (MAP) kinase pathways: Regulation and physiological functions. Endocr. Rev. 2001, 22, 153-183.
14. Beyaert, R.; Cuenda, A.; Vanden Berghe, W.; Plaisance, S.; Lee, J. C.; Haegeman, G.; Cohen, P.; Fiers, W. The p38/RK mitogen-activated protein kinase pathway regulates interleukin-6 synthesis response to tumor necrosis factor. EMBO J. 1996, 15, 1914-1923.
15. Raingeaud, J.; Gupta, S.; Rogers, J. S.; Dickens, M.; Han, J.; Ulevitch, R. J.; Davis, R. J. Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine. J. Biol. Chem. 1995, 270, 7420-7426.
16. Lee, J. C.; Kassis, S.; Kumar, S.; Badger, A.; Adams, J. L. p38 mitogen-activated protein kinase inhibitors-Mechanisms and therapeutic potentials. Pharmacol. Ther. 1999, 82, 389-397.
17. Henry, J. R.; Cavender, D. E.; Wadsworth, S. A. p38 Mitogen-activated protein kinase as a target for drug discovery. Drugs Future 1999, 24, 1345-1354.
18. Salituro, F. G.; Germann, U. A.; Wilson, K. P.; Bemis, G. W.; Fox, T.; Su, M. S. S. Inhibitors of p38 MAP kinase: Therapeutic intervention in cytokine-mediated diseases. Curr. Med. Chem. 1999, 6, 807-823.
19. Boehm, J. C.; Adams, J. L. New inhibitors of p38 kinase. Expert Opin. Ther. Patents 2000, 10, 25-37.
20. Mclay, L. M.; Halley, F.; Souness, J. E.; McKenna, J.; Benning, V.; Birrell, M.; Burton, B.; Belvisi, M.; Collis, A.; Constan, A.; Foster, M.; Hele, D.; Jayyosi, Z.; Kelley, M.; Maslen, C.; Miller, G.; Ouldelhkim, M. C.; Page, K.; Phipps, S.; Pollock, K.; Porter, B.; Ratcliffe, A. J.; Redford, E. J.; Webber, S.; Slater, B.; Thybaud, V.; Wilsher, N. The discovery of RPR 200765A, a p38 MAP kinase inhibitor displaying a good oral antiarthritic efficacy. Bioorg. Med. Chem. 2001, 9, 537-554.
21. Tong, L.; Pav, S.; White, D. M.; Rogers, S.; Crane, K. M.; Cywin, C. L.; Brown, M. L.; Pargellis, C. A. A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket. Nat. Struct. Biol. 1997, 4, 311-316.
22. Wang, Z.; Canagarajah, B. J.; Boehm, J. C.; Kassisa, S.; Cobb, M. H.; Young, P. R.; Abdel-Meguid, S.; Adams, J. L.; Goldsmith, E. J. Structural basis of inhibitor selectivity in MAP kinases. Structure 1998, 6, 1117-1128.
23. Wilson, K. P.; McCaffrey, P. G.; Hsiao, K.; Pazhinisamy, S.; Galullo, V.; Bemis, G. W.; Fitzgibbon, M. J.; Caron, P. R.; Murcko, M. A.; Su, M. S. S. The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase. Chem. Biol. 1997, 4, 423-431.
24. Adams, J. L.; Gallagher, T. F.; Boehm, J. C.; Kassis, S.; Gorycki, P. D.; Gum, R. J.; Webb, E. F.; Sorenson, M. E.; Smietana, J. M.; Garigipati, R. S.; Hall, R. F.; Ayrton, A.; Badger, A.; Griswold, D. E.; Young, P. R.; Lee, J. C. P38 MAP kinase inhibitors: Progress, pitfalls and possibilities. Spec. Publ.-R. Soc. Chem. 2001, 264, 163-173.
25. Gum, R. J.; McLaughlin, M. M.; Kumar, S.; Wang, Z.; Bower, M. J.; Lee, J. C.; Adams, J. L.; Livi, G. P.; Goldsmith, E. J.; Young, P. R. Acquisition of sensitivity of stress-activated protein kinases to the p38 inhibitor, SB 203580, by alteration of one or more amino acids within the ATP binding pocket. J. Biol. Chem. 1998, 273, 15605-15610.
26. Lisnock, J.; Tebben, A.; Frantz, B.; O'Neill, E. A.; Croft, G.; O'Keefe, S. J.; Li, B.; Hacker, C.; de Laszlo, S.; Smith, A.; Libby, B.; Liverton, N.; Hermes, J.; LoGrasso, P. Molecular basis for p38 protein kinase inhibitor specificity. Biochemistry 1998, 37, 16573-16581.
27. Wang, Z.; Canagarajah, B. J.; Boehm, J. C.; Kassisa, S.; Cobb, M. H.; Young, P. R.; Abdel-Meguid, S.; Adams, J. L.; Goldsmith, E. J. Structural basis of inhibitor selectivity in MAP kinases. Structure (London) 1998, 6, 1117-1128.
28. Adams, J. L.; Boehm, J. C.; Kassis, S.; Gorycki, P. D.; Webb, E. F.; Hall, R.; Sorenson, M.; Lee, J. C.; Ayrton, A.; Griswold, D. E.; Gallagher, T. F. Pyrimidinylimidazole inhibitors of CSBP/ p38 kinase demonstrating decreased inhibition of hepatic cytochrome P450 enzymes. Bioorg. Med. Chem. Lett. 1998, 8, 3111-3116.
29. Testa, B.; Jenner, P. Inhibitors of Cytochrome P-450s and their mechanism of action. Drug Metab. Rev. 1981, 12, 1-117.
30. Laufer, S. A.; Striegel, H. G.; Wagner, G. K. Imidazole Inhibitors of Cytokine Release: Probing Substituents in the 2 Position. J. Med. Chem. 2002, 45, 4695-4705.
31. Laufer, S. A.; Wagner, G. K.; Kotschenreuther, D. A.; Albrecht, W. Novel Substituted Pyridinyl Imidazoles as Potent Anticytokine Agents with Low Activity against Hepatic Cytochrome P450 Enzymes. J. Med. Chem. 2003, 46, 3230-3244.
32. Kotschenreuther, D.; Laufer, S. A new and versatile approach towards N-substituted imidazole derivatives. Arch Pharm-Pharm Med Chem 2000, 333, 19.
33. Wagner, G. K.; Kotschenreuther, D.; Zimmermann, W.; Laufer, S. A. Identification of Regioisomers in a Series of N-Substituted Pyridin-4-yl Imidazole Derivatives by Regiospecific Synthesis, GC/MS, and 1H NMR. J. Org. Chem. 2003, 68, 4527-4530.
34. Graymore, J. The Action of Benzoyl Chloride and Hydrogen Sulphide on Cyclic Methylenamines. J. Chem. Soc. 1932, 865-866.
35. Tiollais, R. Aldimine derivatives of acyclic aldehydes. I. Preparation and physical properties of aldimines. II. Stability and spontaneous transformation of the aldimines. Bull. Soc. Chim. Fr. 1947, 708-716.
36. Giumanini, A. G.; Verardo, G.; Zangrando, E.; Lassiani, L. 1,3,5-Triarylhexahydro-sym-triazines and 1,3,5,7-tetraaryl-1,3,5,7-tetrazocines from aromatic amines and paraformaldehyde. J. Prakt. Chem. 1987, 329, 1087-1103.
37. Elam, E. U.; Davis, H. E. Chemistry of dimethylketene dimer. VII. Dimers of dimethylthioketene. J. Org. Chem. 1967, 32, 1562-1565.
38. Liverton, N. J.; Butcher, J. W.; Claiborne, C. F.; Claremon, D. A.; Libby, B. E.; Nguyen, K. T.; Pitzenberger, S. M.; Selnick, H. G.; Smith, G. R.; Tebben, A.; Vacca, J. P.; Varga, S. L.; Agarwal, L.; Dancheck, K.; Forsyth, A. J.; Fletcher, D. S.; Frantz, B.; Hanlon, W. A.; Harper, C. F.; Hofsess, S. J.; Kostura, M.; Lin, J.; Luell, S.; O'Neill, E. A.; Orevillo, C. J.; Pang, M.; Parsons, J.; Rolande, A.; Sahly, Y.; Visco, D. M.; O'Keefe, S. J. Design and Synthesis of Potent, Selective, and Orally Bioavailable Tetra-substituted Imidazole Inhibitors of p38 Mitogen-Activated Protein Kinase. J. Med. Chem. 1999, 42, 2180-2190.
39. Jackson, P. F.; Bullington, J. L. Pyridinylimidazole based p38 MAP kinase inhibitors. Curr. Top. Med. Chem. (Hilversum, Netherlands) 2002, 2, 1011-1020.
40. Boehm, J. C.; Smietana, J. M.; Sorenson, M. E.; Garigipati, R. S.; Gallagher, T. F.; Sheldrake, P. L.; Bradbeer, J.; Badger, A. M.; Laydon, J. T. 1-Substituted 4-Aryl-5-pyridinylimidazoles: A New Class of Cytokine Suppressive Drugs with Low 5-Lipoxygenase and Cyclooxygenase Inhibitory Potency. J. Med. Chem. 1996, 39, 3929-3937.
41. Donat, C.; Laufer, S. In-vitro screening assay to evaluate cytokine release inhibitors. Arch. Pharm.-Pharm. Med. Chem. 2000, 333, 15.
42. Forrer, P.; Tamaskovic, R.; Jaussi, R. Enzyme-linked immunosorbent assay for measurement of JNK, ERK, and p38 kinase activities. Biol. Chem. 1998, 379, 1101-1111.
43. Crespi, C. L.; Miller, V. P.; Penman, B. W. Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Anal. Biochem. 1997, 248, 188-190.